143 related articles for article (PubMed ID: 11122438)
1. Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias.
Sohn JH; Kim DH; Choi NG; Park YE; Ro JY
Histopathology; 2000 Dec; 37(6):555-60. PubMed ID: 11122438
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and nuclear shapes in benign prostate hyperplasia and prostate adenocarcinoma: comparison with and relation to Gleason score.
Choi NG; Sohn JH; Park HW; Jung TY
Int J Urol; 1999 Jan; 6(1):13-8. PubMed ID: 10221859
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Willman JH; Holden JA
Prostate; 2000 Mar; 42(4):280-6. PubMed ID: 10679757
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors.
Rodríguez-Berriguete G; Galvis L; Fraile B; de Bethencourt FR; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
Hum Pathol; 2012 Feb; 43(2):229-37. PubMed ID: 21802116
[TBL] [Abstract][Full Text] [Related]
6. Expression of cysteine protease protein 32 in prostatic adenocarcinoma correlates with tumor grade.
Anwar S; Ambros RA; Jennings TA; Ross JS; Beza A; Mian B; Nazeer T
Arch Pathol Lab Med; 2004 Jun; 128(6):649-52. PubMed ID: 15163235
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
8. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.
Bisegna C; Gravina GL; Pierconti F; Martini M; Larocca L; Rossi P; Grimaldi P; Dolci S; Di Stasi S; Jannini EA
Andrology; 2020 Mar; 8(2):427-433. PubMed ID: 31433119
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.
Häussler O; Epstein JI; Amin MB; Heitz PU; Hailemariam S
Hum Pathol; 1999 Sep; 30(9):1077-86. PubMed ID: 10492043
[TBL] [Abstract][Full Text] [Related]
11. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
12. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
O'Neill AJ; Boran SA; O'Keane C; Coffey RN; Hegarty NJ; Hegarty P; Gaffney EF; Fitzpatrick JM; Watson RW
Prostate; 2001 May; 47(3):183-8. PubMed ID: 11351347
[TBL] [Abstract][Full Text] [Related]
13. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Hughes C; Murphy A; Martin C; Fox E; Ring M; Sheils O; Loftus B; O'Leary J
J Clin Pathol; 2006 Jul; 59(7):721-4. PubMed ID: 16556661
[TBL] [Abstract][Full Text] [Related]
15. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of JNK and p-JNK in advanced prostate cancer and their clinical implications].
Zhang P; Han J; Zheng L; Wang KN; Fan LM; Xie HD; Wang SR; Jiang T
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):309-314. PubMed ID: 29714414
[TBL] [Abstract][Full Text] [Related]
17. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
